Early Access

10-QPeriod: Q1 FY2024

3M CO Quarterly Report for Q1 Ended Mar 31, 2024

Filed April 30, 2024For Securities:MMM

Summary

3M Company reported solid financial results for the first quarter of 2024, with net sales of $8.003 billion, a slight decrease of 0.3% compared to the prior year. However, operating income saw a significant increase of 20.9% to $1.501 billion, driven by improved operating margins and effective cost management. Diluted earnings per share (EPS) were $1.67, a decrease from $1.76 in the prior year, primarily impacted by "special items" related to significant litigation and divestiture costs, which the company adjusts for in its non-GAAP reporting to show underlying operational strength. A major development during the quarter was the completion of the spin-off of its Health Care business, now operating as Solventum Corporation, on April 1, 2024. This strategic move is expected to allow 3M to focus on its core industrial, safety, transportation, electronics, and consumer businesses. The company also continued to manage its significant legal and environmental liabilities, particularly those related to PFAS (per- and polyfluoroalkyl substances) and Combat Arms Earplugs, which continue to impact reported earnings but are being actively addressed through settlements and strategic planning.

Financial Statements
Beta
Revenue$6.02B
Cost of Revenue$3.48B
Gross Profit$2.53B
SG&A Expenses$1.13B
Operating Expenses$4.87B
Operating Income$1.15B
Interest Expense$137.00M
Net Income$928.00M
EPS (Basic)$1.67
EPS (Diluted)$1.67
Shares Outstanding (Basic)555.00M
Shares Outstanding (Diluted)555.90M

Key Highlights

  • 1Net sales for Q1 2024 were $8.003 billion, a slight 0.3% decrease year-over-year.
  • 2Operating income increased by a substantial 20.9% to $1.501 billion, reflecting improved operational efficiency and cost controls.
  • 3Diluted EPS was $1.67, down from $1.76 in Q1 2023, largely due to "special items" including litigation and divestiture costs.
  • 4The company completed the spin-off of its Health Care business (Solventum) on April 1, 2024, to sharpen its strategic focus.
  • 5The Safety and Industrial segment showed resilience with a 9.3% increase in operating income, while Transportation and Electronics saw a significant 63.5% surge in operating income.
  • 6Free cash flow for the quarter was $392 million, a decrease from $800 million in the prior year, impacted by higher litigation payments.
  • 73M continues to address significant legal liabilities, particularly related to PFAS and Combat Arms Earplugs, with ongoing settlement activities and provisions.

Frequently Asked Questions